Eton Pharmaceuticals reports record Q2 revenue, raises 2026 guidance

Eton Pharmaceuticals (NASDAQ: ETON ) reported second-quarter financial results on Thursday.

The transcript from the company's second-quarter earnings call has been provided below.

APIs provide real-time access to earnings call transcripts and financial data.

Visit to learn more.

Access the full call at Summary Eton Pharmaceuticals reported a record revenue of $37.6 million for Q2 2026, marking a 99% year-over-year increase, driven by the successful relaunch of Hemangiol and strong performances across its product portfolio.

The company raised its 2026 revenue guidance to over $145 million and expects a full-year adjusted EBITDA margin to exceed 35%, showcasing significant profitability and operational leverage.

Strategic initiatives included the acquisition of U.S. rights to Impavido and licensing of ASN001, expanding Eton's portfolio in pediatric dermatology and rare diseases, with ASN001 expected to become the largest product.

Operational highlights include the rapid transition of Hemangiol's patient base to a new distribution model, successful progress on R&D projects like the KindiVI label expansion, and FDA Fast Track designation for Emglidea.

Management emphasized the scalability of their business model, the potential for ASN001 to complement Hemangiol in treating infantile hemangiomas, and a strategic focus on expanding their rare disease therapy portfolio without external financing.

Full Transcript OPERATOR Good afternoon and welcome to the Eton Pharmaceuticals Second Quarter 2026 Financial Results Conference Call.

At this time, all participants are in listen-only mode.

Following the formal remarks, we will open the call up for your questions.

Please be advised this call is being recorded at the company's request.

At this time, I'd like to turn the call over to David Krempa, Chief Business Officer at Eton Pharmaceuticals.

Please proceed.

David Krempa, Chief Business Officer Thank you, operator.

Good afternoon everyone and welcome to Eton's second quarter 2026 conference call.

This afternoon we issued a press release that outlines the topics we plan to discuss on today's call.

The release is available on our website, etonpharma.com.

Joining me on our call today, we have Sean Brynjelsen, our CEO, Epek Trinkus, our Chief Commercial Officer, and Judy Matthews, our Chief Financial Officer.

Before we begin, I would like to remind everyone that today's remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements.

Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC.

Now I will turn the call over to our CEO, Sean Brynjelsen.

Sean Brynjelsen, CEO Thank you, David.

Good afternoon, everyone, and thank you for joining us today.

We had an exceptional second quarter with record revenue, significant margin expansion, and important progress across both our commercial portfolio and pipeline.

We also completed several strategic transactions that we believe will support Eton's continued long-term growth.

I'll begin by highlighting a few of the quarter's key accomplishments.

We once again achieved record revenue, delivering 99% year-over-year growth with contributions from across the portfolio.

At the same time, we delivered significant margin expansion and accelerated adjusted EBITDA and net income growth.

We established a strong commercial foundation in pediatric dermatology with the successful relaunch of Hemangiol, which is already performing ahead of our expectations.

We expanded our portfolio through the acquisition of U.S. rights to Impavido and the licensing of ASN001, adding both a commercial rare disease product and a late-stage development candidate that we believe has the potential to become the largest product in our portfolio.

And finally, we had a very productive few months on the R&D front.

We submitted a prior approval supplement for the KindiVI label expansion, initiated the ET-700 pilot study, began preparations for the Increlex label harmonization study, and also received Fast Track designation for Emglidea.

Starting with the financials, it was another record quarter for Eton.

Revenue reached $37.6 million, an increase of 99% year over year.